Abstract
This work studies fundamental questions regarding the optimal design of antimicrobial treatment protocols, using pharmacodynamic and pharmacokinetic mathematical models. We consider the problem of designing an antimicrobial treatment schedule to achieve eradication of a microbial infection, while minimizing the area under the time-concentration curve (AUC), which is equivalent to minimizing the cumulative dosage. We first solve this problem under the assumption that an arbitrary antimicrobial concentration profile may be chosen, and prove that the ideal concentration profile consists of a constant concentration over a finite time duration, where explicit expressions for the optimal concentration and the time duration are given in terms of the pharmacodynamic parameters. Since antimicrobial concentration profiles are induced by a dosing schedule and the antimicrobial pharmacokinetics, the ‘ideal’ concentration profile is not strictly feasible. We therefore also investigate the possibility of achieving outcomes which are close to those provided by the ‘ideal’ concentration profile, using a bolus+continuous dosing schedule, which consists of a loading dose followed by infusion of the antimicrobial at a constant rate. We explicitly find the optimal bolus+continuous dosing schedule, and show that, for realistic parameter ranges, this schedule achieves results which are nearly as efficient as those attained by the ‘ideal’ concentration profile. The optimality results obtained here provide a baseline and reference point for comparison and evaluation of antimicrobial treatment plans.
Similar content being viewed by others
Data Availability
All data generated or analysed during this study are included in the article.
References
Ali A, Imran M, Sial S, Khan A (2022) Effective antimicrobial dosing in the presence of resistant strains. PLoS ONE 17:e0275762. https://doi.org/10.1371/journal.pone.0275762
Austin DJ, White NJ, Anderson RM (1998) The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theor Biol 194:313–339. https://doi.org/10.1006/jtbi.1997.0438
Bhagunde PR, Nikolaou M, Tam VH (2015) Modeling heterogeneous bacterial populations exposed to antibiotics: the logistic dynamics case. AIChE J 61:2385–2393. https://doi.org/10.1002/aic.14882
Bouvier d’Yvoire MJ, Maire PH (1996) Dosage regimens of antibacterials. Clin Drug Invest 11:229–239. https://doi.org/10.2165/00044011-199611040-00006
Brauner A, Fridman O, Gefen O, Balaban NQ (2016) Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol 14:320–330
Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL (2019) Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans. Antimicrob Agents Chemother 63:e02307-18. https://doi.org/10.1128/AAC.02307-18
Cicchese JM, Pienaar E, Kirschner DE, Linderman JJ (2017) Applying optimization algorithms to tuberculosis antibiotic treatment regimens. Cell Mol Bioeng 10:523–535. https://doi.org/10.1007/s12195-017-0507-6
Cogan NG (2006) Effects of persister formation on bacterial response to dosing. J Theor Biol 238:694–703. https://doi.org/10.1016/j.jtbi.2005.06.017
Cogan NG, Brown J, Darres K, Petty K (2012) Optimal control strategies for disinfection of bacterial populations with persister and susceptible dynamics. Antimicrob Agents Chemother 56:4816–4826. https://doi.org/10.1128/aac.00675-12
Colin PJ, Eleveld DJ, Thomson AH (2020) Genetic algorithms as a tool for dosing guideline optimization: application to intermittent infusion dosing for vancomycin in adults. CPT Pharmacometrics Syst Pharmacol 9:294–302. https://doi.org/10.1002/psp4.12512
Corvaisier S, Maire PH, Bouvier d’Yvoire MY, Barbaut X, Bleyzac N, Jelliffe RW (1998) Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob Agents Chemother 42:1731–1737. https://doi.org/10.1128/AAC.42.7.1731
Czock D, Keller F (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 34:727–751. https://doi.org/10.1007/s10928-007-9069-x
Derendorf H, Schmidt S (2019) Rowland and Tozer’s clinical pharmacokinetics and pharmacodynamics: concepts and applications. Wolters Kluwer, South Holland
de Velde F, Mouton JW, de Winter BC, van Gelder T, Koch BC (2018) Clinical applications of population pharmacokinetic models of antibiotics: challenges and perspectives. Pharmacol Res 134:280–288. https://doi.org/10.1016/j.phrs.2018.07.005
Geli P, Laxminarayan R, Dunne M, Smith DL (2012) One-size-fits-all? Optimizing treatment duration for bacterial infections. PLoS ONE 7:e29838. https://doi.org/10.1371/journal.pone.0029838
Goranova M, Ochoa G, Maier P, Hoyle A (2022) Evolutionary optimisation of antimicrobial dosing regimens for bacteria with different levels of resistance. Artif. Intell. Med. 133:102405. https://doi.org/10.1016/j.artmed.2022.102405
Hoyle A, Cairns D, Paterson I, McMillan S, Ochoa G, Desbois AP (2020) Optimising efficacy of antimicrobials against systemic infection by varying dosage quantities and times. PLoS Comput. Biol. 16:e1008037. https://doi.org/10.1371/journal.pcbi.1008037
Kesisoglou I, Tam VH, Tomaras AP, Nikolaou M (2022) Discerning in vitro pharmacodynamics from OD measurements: A model-based approach. Comput Chem Eng 158:107617. https://doi.org/10.1016/j.compchemeng.2021.107617
Khan A, Imran M (2018) Optimal dosing strategies against susceptible and resistant bacteria. J Biol Syst 26:41–58. https://doi.org/10.1142/S0218339018500031
Krzyzanski W, Jusko WJ (1998) Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci 87:67–72. https://doi.org/10.1021/js970168r
Ledzewicz U, Schättler H (2021) On the role of pharmacometrics in mathematical models for cancer treatments. Discrete Contin Dyn Syst Ser B 26:483–499. https://doi.org/10.3934/dcdsb.2020213
Leszczyński M, Ledzewicz U, Schättler H (2020) Optimal control for a mathematical model for chemotherapy with pharmacometrics. Math Model Nat Phenom 15:69. https://doi.org/10.1051/mmnp/2020008
Levin BR, Udekwu KI (2010) Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments. Antimicrob Agents Chemother 54:3414–3426. https://doi.org/10.1128/AAC.00381-10
Lipsitch M, Levin BR (1997) The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 41:363–373. https://doi.org/10.1128/AAC.41.2.363
Macheras P, Iliadis A (2016) Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics: homogeneous and heterogeneous approaches. Springer, Heidelberg
Marrec L, Bitbol AF (2020) Resist or perish: fate of a microbial population subjected to a periodic presence of antimicrobial. PLoS Comput Biol 16:e1007798. https://doi.org/10.1371/journal.pcbi.1007798
Meibohm B, Derendorf H (1997) Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 35:401–413
Mi K, Zhou K, Sun L, Hou Y, Ma W, Xu X, Huo M, Liu Z, Huang L (2022) Application of semi-mechanistic pharmacokinetic and pharmacodynamic model in antimicrobial resistance. Pharmaceutics 14:246. https://doi.org/10.3390/pharmaceutics14020246
Morsky B, Vural DC (2022) Suppressing evolution of antibiotic resistance through environmental switching. Theor Ecol 15:115–127. https://doi.org/10.1007/s12080-022-00530-4
Mouton JW, Vinks AS (2005) Pharmacokinetic/Pharmacodynamic modelling of antibiotics in vitro and in vivo using bacterial growth and kill kinetics: the zMIC vs stationary concentrations. Clin Pharmacokinet 44:201–10. https://doi.org/10.2165/00003088-200544020-00005
Mudassar I, Smith H (2005) The pharmacodynamics of antibiotic treatment. Comput Math Methods Med 7:229–263. https://doi.org/10.1080/10273660601122773
Mueller M, de la Pena A, Derendorf H (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 48:369–377. https://doi.org/10.1128/AAC.48.2.369-377.2004
Murray CJ, Ikuta KS, Sharara F et al (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
Nguyen HM, Peletier LA (2009) Monotonicity of time to peak response with respect to drug dose for turnover models. Differ Int Equ 22:1–26
Nielsen EI, Friberg LE (2013) Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 65:1053–1090. https://doi.org/10.1124/pr.111.005769
Nikolaou M, Tam VH (2006) A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations. J Math Biol 52:154–182. https://doi.org/10.1007/s00285-005-0350-6
Nikolaou M, Schilling AN, Vo G, Chang KT, Tam VH (2007) Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents. Ann Biomed Eng 35:1458–1470. https://doi.org/10.1007/s10439-007-9306-x
Onufrak NJ, Forrest A, Gonzalez D (2016) Pharmacokinetic and pharmacodynamic principles of anti-infective dosing. Clin Ther 38:1930–1947. https://doi.org/10.1016/j.clinthera.2016.06.015
Owens RC, Nightingale CH, Ambrose PG (eds) (2004) Antibiotic optimization: concepts and strategies in clinical practice. Marcel Dekker, New York
Paterson IK, Hoyle A, Ochoa G, Baker-Austin C, Taylor NG (2016) Optimising antimicrobial usage to treat bacterial infections. Sci Rep 6:1–10. https://doi.org/10.1038/srep37853
Peletier LA, Gabrielsson J, Haag JD (2005) A dynamical systems analysis of the indirect response model with special emphasis on time to peak response. J Pharmacokinet Pharmacodyn 32:607–654. https://doi.org/10.1007/s10928-005-0047-x
Peña-Miller R, Lähnemann D, Schulenburg H, Ackermann M, Beardmore R (2012) Selecting against antibiotic-resistant pathogens: optimal treatments in the presence of commensal bacteria. Bull Math Biol 74:908–934. https://doi.org/10.1007/s11538-011-9698-5
Rayner CR, Smith PF et al (2021) Model informed drug development for anti?infectives: state of the art and future. Clin Pharmacol Ther 109:867–891. https://doi.org/10.1002/cpt.2198
Rao GG, Landersdorfer CB (2021) Antibiotic pharmacokinetic/pharmacodynamic modelling: zMIC, pharmacodynamic indices and beyond. Int J Antimicrob Agents 58:106368. https://doi.org/10.1016/j.ijantimicag.2021.106368
Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR (2004) Pharmacodynamic functions: a multiparameter approach to the design of antimicrobial treatment regimens. Antimicrob Agents Chemother 48:3670–3676. https://doi.org/10.1128/AAC.48.10.3670-3676.2004
Rescigno A (2003) Foundations of pharmacokinetics. Springer, New York
Rotschafer JC, Andes DR, Rodvold KA (eds) (2016) Antibiotic pharmacodynamics. Springer, New York
Shi J, Alagoz O, Erenay FS, Su Q (2014) A survey of optimization models on cancer chemotherapy treatment planning. Ann Oper Res 221:331–356. https://doi.org/10.1007/s10479-011-0869-4
Singh G, Orman MA, Conrad JC, Nikolaou M (2023) Systematic design of pulse dosing to eradicate persister bacteria. PLoS Comput Biol 19:e1010243. https://doi.org/10.1371/journal.pcbi.1010243
Smith NM, Lenhard JR et al (2020) Using machine learning to optimize antimicrobial combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect 26:1207–1213. https://doi.org/10.1016/j.cmi.2020.02.004
Tindall M, Chappell MJ, Yates JW (2022) The ingredients for an antimicrobial mathematical modelling broth. Int J Antimicrob Agents 60:106641. https://doi.org/10.1016/j.ijantimicag.2022.106641
Ventola CL (2015) The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther 40:277
Vinks AA, Derendorf H, Mouton JW (eds) (2014) Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. Springer, New York
Wen X, Gehring R, Stallbaumer A, Riviere JE, Volkova VV (2016) Limitations of zMIC as sole metric of pharmacodynamic response across the range of antimicrobial susceptibilities within a single bacterial species. Sci Rep 6:1–8. https://doi.org/10.1038/srep37907
Wu X, Zhang H, Li J (2022) An analytical approach of one-compartmental pharmacokinetic models with sigmoidal hill elimination. Bull Math Biol 84:117. https://doi.org/10.1007/s11538-022-01078-4
Zhi J, Nightingale CH, Quintiliani R (1988) Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinetic Biopharm 16:355–375. https://doi.org/10.1007/BF01062551
Zilonova EM, Bratus AS (2016) Optimal strategies in antibiotic treatment of microbial populations. Appl Anal 95:1534–1547. https://doi.org/10.1080/00036811.2016.1143552
Acknowledgements
I am grateful to the referees for comments and suggestions which have led to improvement of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendices
Appendix A Proof of Lemma 1
Using assumptions (I), (II) and the assumption \( \alpha >1\), we have
These facts imply that \(f_r(c)\) has a global maximizer on \((0,\infty )\), which we denote by \(c_{opt}\).
It remains to show that \(c_{opt}\) is the unique critical point of \(f_r(c)\). We have
where
so any critical point of \(f_r(c)\) satisfies \(h(c)=r\). Note that
hence:
(a) if k is concave then \(h'(c)>0\), so h(c) is increasing in \((0,\infty )\), hence the critical point \(c_{opt}\) of \(f_r(c)\) is unique.
(b) If k is sigmoidal, then \(h'(c)>0\) for \(c>c_{infl}\), hence h(c) is increasing in this range, so that \(f_r(c)\) has at most one critical point in the interval \([c_{infl},\infty )\). To prove uniqueness it therefore suffices to show that \(f_r(c)\) has no critical point in \([0,c_{infl}]\). But note that since k(c) is convex on \([0,c_{infl}]\), hence \(k'(c)\) is increasing on this interval, we have
hence, by (A1), \(f_r'(c)>0\) for \(c\in (0,c_{infl}]\). Note that this also shows that \(c_{opt}>c_{infl}\).
Appendix B Proof of Theorem 2
(i) is trivially true, since if \(\hat{T}>T_{opt}\) then \(C_{opt}(t)\) leads to eradication before time \(\hat{T}\), and, by Theorem 1 it achieves the lowest possible value of AUC.
(ii) If \(\hat{T}\le T_{min}\) then for any \(T\le \hat{T}\) we have
so that the target reduction cannot be achieved.
(iii) Assume now that
Note first that \(\hat{T}>T_{min}\) implies that, using assumption (II),
hence by (I) the equation (26) has a unique solution \(\hat{c}\).
(26) implies that
so that the profile \(\hat{C}(t)\) achieves eradication at time \(\hat{T}\).
To show that \(\hat{C}(t)\), defined by (25) is the solution of Problem 2, we assume that C(t) is any concentration profile for which \(LR(T)=LR_{target}\), where \(T\le \hat{T}\), and we need to show that if \(AUC[C(t)]\ge AUC[\hat{C}(t)]\), with equality iff \(C(t)=\hat{C}(t)\) for a.e. t.
By (26),(B1), and (15), we have
which, by (I), implies
We now define
and claim that
To show this we recall that in the proof of Lemma 1 (Appendix A) it was shown that the function h(c) defined by (A2) is monotone increasing for all \(c>0\) in the concave case, and for all \(c>c_{infl}\) in the sigmoidal case, in which case we also have \(c_{opt}>c_{infl}\). Therefore, since \(h(c_{opt})=r\) and \(h(\hat{c})=\hat{r}\), (B2) implies (B4).
By (B3) we have
which, using Lemma 1, applied with \(\hat{r}\) replacing r, implies that \(\hat{c}\) is the maximizer of \(f_{\hat{r}}(c)\), so that
We therefore have, for all \(c>0\),
If C(t) is a concentration profile for which \(LR(T)=LR_{target}\), where \(T\le \hat{T}\), then we have, using (B4),(B5)
which, togther with (26), implies
proving that \(\hat{C}(t)\) indeed attains the minimal AUC among the relevant concentration profiles. To show uniqueness, note that the equality \(AUC[C(t)]=AUC[\hat{C}(t)]\) can hold only if all inequalities in (B6) are in fact equalities, which in particular implies \(T=\hat{T}\) and \(k(C(t))=k(\hat{c})\), hence \(C(t)=\hat{c}\) for a.e. \(0\le t\le \hat{T}\), and also that \(\int _{\hat{T}}^\infty C(t)dt=0\), so that \(C(t)=0\) for a.e. \(t> \hat{T}\), hence \(C(t)=\hat{C}(t)\) a.e..
Appendix C Proof of Theorem 3
To begin the analysis leading to Theorem 3, we calculate the values \(LR_{max}\) and AUC corresponding to a bolus+continuous dosing schedule.
Lemma 2
Consider a bolus+continuous schedule \(d_{bc}(t)\) (see (36)), with \(\bar{c}>zMIC\), and the induced antimicrobial concentration profile \(C_{bc}(t)\) (see (37)). Then:
(i) The maximal log-reduction corresponding to this concentration profile is
where the function \(\phi (c)\) is defined by:
(ii) The AUC corresponding to this dosage schedule is
Proof
(i) By (10), the log-reduction of the microbial load corresponding to (37), at time T, is
hence
and
We thus have that LR(T) is an increasing function for \(T<T_{bc}\), and a decreasing function for sufficiently large T, so that its maximum attained at some \(T^*>T_{bc}\) satisfying \(LR'(T^*)=0\), that is
Using the change of variable \(u=\bar{c}e^{-k_e\cdot (t-T_{bc})}\) in the integral below, we conclude that
where the function \(\phi \) is defined by (C2).
(ii) Using (34), the AUC corresponding to the concentration profile generated by the dosing schedule (36) is given by
\(\square \)
Proof of Theorem 3
By (C1), in order to achieve a given log-reduction \(LR_{target}\) using a dosing schedule of the form (36), the parameters \(\bar{c},T_{bc}\) defining this schedule must satisfy the constraint \(LR_{max}[C(t)]=LR_{target}\), or
We need to minimize the expression (C3) over \((\bar{c},T_{bc})\), under the constraints (C4) and
The constraint (C4) can be written as
and the inequality constraints (C5) imply that \(\bar{c}\) must satisfy
where \(c^*\) is the solution of (44).
Substituting (C6) into (C3) we get
which must be minimized over \(\bar{c}\) satisfying (C7). Noting that the expression (C8) goes to \(+\infty \) when \(\bar{c}\rightarrow zMIC\), we see that the minimum is attained either at (a) an interior point of the interval (C7), or (b) at \(\bar{c}=c^*\).
If \(c_{opt}<c^*\), then since \(c_{opt}\) is the maximizer of \(f_r(c)\) given by (13), we have
so that the minimum of \(AUC(\bar{c})\) in the interval (C7) is attained at an interior point, at which \(AUC'(\bar{c})\) must vanish, and using the fact that \(\phi '(c)=\frac{k(c)-r}{c}\) we compute
Thus, from (C6) we get (40), and from (C3) we get (43).
On the other hand, if \(c_{opt}\ge c^*\), the above calculation shows that the derivative of \(AUC(\bar{c})\) does not vanish in the interior of the interval (C7), so that the minimum is attained at \(\bar{c}=c^*\), proving part (ii) of the theorem. \(\square \)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Katriel, G. Optimizing Antimicrobial Treatment Schedules: Some Fundamental Analytical Results. Bull Math Biol 86, 1 (2024). https://doi.org/10.1007/s11538-023-01230-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11538-023-01230-8